| Identification | Back Directory | [Name]
5-Phenyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide | [CAS]
612530-44-6 | [Synonyms]
PTP1B-IN-1
PTP1B inhibitor 1
1,1-Dioxo-5-phenyl-1,2,5-thiadiazolidin-3-one
5-Phenyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide
1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide | [Molecular Formula]
C8H8N2O3S | [MDL Number]
MFCD18206847 | [MOL File]
612530-44-6.mol | [Molecular Weight]
212.23 |
| Chemical Properties | Back Directory | [density ]
1.483 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 38 mg/mL (179.05 mM) | [form ]
Powder | [pka]
4.23±0.20(Predicted) | [color ]
White to yellow | [InChI]
InChI=1S/C8H8N2O3S/c11-8-6-10(14(12,13)9-8)7-4-2-1-3-5-7/h1-5H,6H2,(H,9,11) | [InChIKey]
LDCZCUKQWRZSDT-UHFFFAOYSA-N | [SMILES]
S1(=O)(=O)N(C2=CC=CC=C2)CC(=O)N1 |
| Hazard Information | Back Directory | [Uses]
5-Phenyl-1,2,5-thiadiazolidin-3-one 1,1-Dioxide is used in the structure-based design of protein tyrosine phosphatase-1B inhibitors. | [in vivo]
PTP1B-IN-1 (0.1-1 μg, intrathecal injection, single dose) inhibits ER stress and NF-κB activation, exhibits analgesic and anti-inflammatory effects in rats spared nerve injury (SNI) models[3].
| Animal Model: | Rats SNI models[3] | | Dosage: | 0.1-1 μg | | Administration: | intrathecal injection, single dose | | Result: | Increased the paw withdrawal threshold (PWT). |
|
|
|